In latest blow to Teva, CGRP migraine med could be delayed while rivals race towards the finish line
It’s starting to feel like Teva $TEVA can’t catch a break. After an incredibly rough series of events that led to massive layoffs, restructuring, and political upheaval, now Teva has quietly signaled to investors that the launch of its CGRP migraine med could be delayed.
Teva’s stock has tumbled nearly 10% in pre-market trading on the news.
Teva’s drug, called fremanezumab (TEV-48125), came up with some impressive Phase III data last fall, with 41% of patients on their CGRP drug seeing their migraine days cut in half, compared to 18% on the placebo. The double blast of data underscores the late-stage race to regulators as some big and small players angle for a slice of the new CGRP migraine market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.